In the complex world of healthcare, where the line between patient care and profit can be blurred, the role of pharmacy benefit managers (PBMs) has come under intense scrutiny. These middlemen, who negotiate drug prices and manage prescription benefits, have been accused of driving up costs and stifling competition. But what makes this issue particularly fascinating is the extent to which PBMs, along with other 'Big Medicine' conglomerates, have captured the healthcare system, leaving patients and providers struggling under the weight of soaring expenses. From the perspective of an expert, I'd like to delve into this topic, exploring the implications and potential solutions, while also reflecting on the broader trends and cultural insights at play.
The PBM Problem
The 'big three' PBMs, namely CVS Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum Rx, control a staggering 80% of U.S. prescriptions. This market dominance, combined with their vertical integration with major insurance and pharmacy chains, has led to a situation where drug costs are inflated, and independent pharmacies are pushed out of business. The Federal Trade Commission's report in 2025 revealed that these PBMs paid their affiliated pharmacies up to 7,736% more than unaffiliated competitors, highlighting the extent of their market power.
What many people don't realize is that this isn't just a PBM issue. The 'Big Medicine' problem extends beyond these middlemen to include insurance conglomerates and wholesale drug distributors. These entities, such as McKesson, Cencora, and Cardinal Health, control a significant portion of the U.S. drug distribution network and are also vertically integrated with medical providers, creating conflicts of interest. For instance, Cencora's agreement to pay $1 million in March 2026 to resolve allegations of kickbacks to healthcare providers demonstrates how these wholesalers can influence drug choices, prioritizing profit margins over clinical judgment.
The Broader Healthcare Crisis
Americans receive middling healthcare quality yet face the highest medical costs in the world. Six of the country's 15 most valuable companies are 'Big Medicine' conglomerates, generating nearly $34 billion in profits last year. This concentration of economic power in the healthcare sector has led to a situation where patients are often left with limited options and high out-of-pocket expenses. The abuse of patents by Big Pharma to keep drug costs high and block competition from generics further exacerbates this crisis.
The Need for Reform
Lawmakers have finally taken steps to address these issues, with the passing of a spending bill in February that banned PBMs from pocketing manufacturer rebates and excluded independent pharmacies from Medicare Part D networks. However, these reforms only scratch the surface. The 'Break Up Big Medicine Act', introduced by Sens. Elizabeth Warren and Josh Hawley, aims to break up all six of the Big Medicine companies to lower healthcare costs and promote competition. This legislation would prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers, including medical practices and pharmacies.
Public Support and Future Implications
Public support for such reforms is growing, with over 80% of voters agreeing that health insurance companies have too much control over medical decisions and drive up costs. Business leaders like Mark Cuban, the billionaire co-founder of Cost Plus Drugs, endorse breaking up these companies. My organization, the American Economic Liberties Project, is part of a coalition that supports the Break Up Big Medicine Act. This legislation, if passed, would begin the path to recovery for the U.S. healthcare system, which is currently under the catastrophic threat of 'Big Medicine'.
Conclusion
In my opinion, the healthcare system in the U.S. is at a critical juncture. The concentration of economic power in the hands of a few 'Big Medicine' conglomerates has led to a crisis where patients are often left with limited options and high out-of-pocket expenses. The Break Up Big Medicine Act, if enacted, would be a significant step towards a more competitive and patient-centered healthcare system. However, it won't heal all the system's problems. It's a start, and one that's long overdue. As an expert, I believe that addressing the 'Big Medicine' problem is essential for the future of healthcare in the U.S., and it's a conversation that needs to continue.
